NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics reported Q3 2026 revenue of $209 million, up 11% year-over-year, with clinical services revenue up 13% to $195 million driven by 29% NGS growth. Profitability improved sharply: GAAP net loss narrowed 72% to $8 million, GAAP gross margin expanded 340 bps to 46%, and adjusted EBITDA rose 53% to $19 million. The company raised FY2026 guidance to $807M-$809M in revenue and approximately $60M in adjusted EBITDA. Separately, the company announced a planned succession in which President and COO Warren Stone becomes CEO on January 4, 2027, with Tony Zook moving to Executive Chairman.
Key figures
- Revenue
- 209254000
- Guidance
- FY2026 revenue raised to $807M-$809M (from $802M-$806M), net loss $(32)M-$(30)M (from $(42)M-$(34)M), adjusted EBITDA approximately $60M (from $56M-$58M)
- Revenue Yoy
- 11%
- Adjusted ebitda
- 18669000
- Clinical revenue
- $195 million, +13% YoY
- Gaap gross margin
- 46%
- Ngs revenue growth
- 29%
- Adjusted ebitda yoy
- 53%
- Adjusted net income
- 10518000
- Adjusted diluted eps
- 0.07
- Cash and equivalents
- 139281000
- Adjusted gross margin
- 49%
- Convertible notes net
- 374688000
- Clinical volume growth
- 1.8%
- Average revenue per test
- 530
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.